PT-141

PT-141 (bremelanotide) is a prescription medicine given by injection under medical supervision — not a cosmetic. Its most common side effect is nausea, which was a frequent reason for stopping in trials; flushing, headache, and injection-site reactions are also common. It can cause transient increases in blood pressure and decreases in heart rate, so it is not recommended in people with uncontrolled hypertension or cardiovascular disease. Focal hyperpigmentation (including of the face, gums, and breasts) has been reported, more with repeated dosing.

Yes. PT-141 was approved by the FDA in 2019 as bremelanotide (brand name Vyleesi) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, given by subcutaneous injection under medical supervision. Approval was based on two randomized, placebo-controlled phase 3 trials (the RECONNECT program); the average benefit is modest, and approval is specific to that indication and population.

PT-141 (bremelanotide) is a melanocortin-receptor agonist. It activates melanocortin receptors — including MC4R in the central nervous system — a pathway associated with sexual-response signaling. This mechanism is characterized in pharmacology studies and supported by randomized clinical trials for the approved indication.

No. The approved medicine is bremelanotide (Vyleesi), a regulated prescription product. Material sold as 'PT-141' by research-chemical vendors outside that approved product is not quality-controlled and is not the regulated medicine.

The evidence is graded high for its approved use: it is supported by randomized, placebo-controlled phase 3 trials and FDA approval. However, the benefit is modest on average and is established only for acquired, generalized HSDD in premenopausal women — not for other populations or uses. It is worth noting that the pivotal trials were manufacturer-sponsored (Palatin Technologies and AMAG Pharmaceuticals, the developer/marketer of bremelanotide).

Both are melanocortin-receptor agonists, but they differ sharply in regulatory status and safety. Melanotan II is an unlicensed research chemical that is not approved for human use; most of its evidence is from animal studies, human data are limited, and unregulated use has been associated with changes in moles/pigmented skin lesions (including a case report of melanoma). PT-141 (bremelanotide) is a separate, FDA-approved melanocortin-agonist prescription medicine (Vyleesi), covered in its own entry. This is a comparison of what each one is and its approval status — not a claim that either is more effective than the other.